Figure 1. Meta-Analysis of Overall Survival and Progression-Free Survival With Nivolumab and Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma.
A, Forest plot and meta-analysis of overall survival with nivolumab and ipilimumab vs nivolumab alone in advanced cancers other than melanoma show no improvement in overall survival with the combination (pooled hazard ratio, 0.95; 95% CI, 0.85-1.06; P = .36; I2 = 0%). B, Forest plot and meta-analysis of progression-free survival with nivolumab and ipilimumab vs nivolumab alone in advanced cancers other than melanoma show marginal, but not clinically meaningful, improvement in progression-free survival with the combination (pooled hazard ratio, 0.88; 95% CI, 0.79-0.98; P = .02; I2 = 0%).